SCHEMBL96174

SCHEMBL96174

[CH2]c1ccc(NC(=O)Cc2ccccc2Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ5 P48544 7/20 0.68
KCNJ3 P48549 7/20 0.68
KCNJ6 P48051 3/20 0.56
CLK2 P49760 1/20 0.54
PRKX P51817 1/20 0.54
CAMK2D Q13557 1/20 0.54
PKN2 Q16513 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54
STK17A Q9UEE5 1/20 0.54
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
THRB P10828 1/20 0.52
ANO1 Q5XXA6 1/20 0.51
P2RX4 Q99571 2/20 0.50
MAPK8 P45983 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15741746 0.84 KCNJ5 (0.68) KCNJ5KCNJ3KCNJ6CLK2PRKX
SCHEMBL4685295 0.83 KCNJ5 (0.66) KCNJ5KCNJ3KCNJ6CLK2PRKX
SCHEMBL30502369 0.81 KCNJ5 (0.68) KCNJ5KCNJ3KCNJ6CLK2PRKX
SCHEMBL15741788 0.80 KCNJ5 (0.65) KCNJ5KCNJ3KCNJ6CLK2PRKX
SCHEMBL95063 0.78 RAB9A (0.56) NPC1RAB9AALDH1A1CYP1A2CYP2D6
SCHEMBL16887459 0.78 ALDH1A1 (0.76) KCNJ5KCNJ3KCNJ6CLK2PRKX
SCHEMBL5852192 0.77 EPHX2 (0.76) NPC1RAB9AALDH1A1LMNAPOLB
SCHEMBL2184203 0.76 RORA (0.71) KCNJ5KCNJ3NPC1RAB9AANO1
SCHEMBL19576522 0.76 KCNJ5 (0.56) KCNJ5KCNJ3KCNJ6CLK2PRKX
SCHEMBL31729852 0.75 KCNJ5 (0.74) KCNJ5KCNJ3KCNJ6CLK2PRKX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB KCNJ5 2576/4885KCNJ3 2957/4885KCNJ6 2671/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 KCNJ5 1616/4885KCNJ3 2532/4885KCNJ6 1293/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 KCNJ5 1616/4885KCNJ3 2532/4885KCNJ6 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.